Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
|
摘要
Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells(APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor immunity is frequently repressed at tumor sites. Malignantly transformed cells rarely survive the attack by the immune system, but cells that do survive change their phenotypes to reduce their immunogenicity. The resultant cells evade the attack by the immune system and form clinically discernible tumors. Tumor microenvironments simultaneously contain a wide variety of immune suppressive molecules and cells to dampen tumor immunity. Moreover, the liver microenvironment exhibits immune tolerance to reduce aberrant immune responses to massively-exposed antigens via the portal vein, and immune dysfunction is frequently associated with liver cirrhosis, which is widespread in hepatocellular carcinoma(HCC) patients. Immune therapy aims to reduce tumor burden, but it is also expected to prevent non-cancerous liver lesions from progressing to HCC, because HCC develops or recurs from noncancerous liver lesions with chronic inflammatory states and/or cirrhosis and these lesions cannot be cured and/or eradicated by local and/or systemic therapies. Nevertheless, cancer immune therapy should augment specific tumor immunity by using two distinct measures: enhancing the effector cell functions such as antigen presentation capacity of APCs and tumor cell killing capacity of cytotoxic cells, and reactivating the immune system in immune-suppressive tumor microenvironments. Here, we will summarize the current status and discuss the future perspective on immune therapy for HCC.
Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells(APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor immunity is frequently repressed at tumor sites. Malignantly transformed cells rarely survive the attack by the immune system, but cells that do survive change their phenotypes to reduce their immunogenicity. The resultant cells evade the attack by the immune system and form clinically discernible tumors. Tumor microenvironments simultaneously contain a wide variety of immune suppressive molecules and cells to dampen tumor immunity. Moreover, the liver microenvironment exhibits immune tolerance to reduce aberrant immune responses to massively-exposed antigens via the portal vein, and immune dysfunction is frequently associated with liver cirrhosis, which is widespread in hepatocellular carcinoma(HCC) patients. Immune therapy aims to reduce tumor burden, but it is also expected to prevent non-cancerous liver lesions from progressing to HCC, because HCC develops or recurs from noncancerous liver lesions with chronic inflammatory states and/or cirrhosis and these lesions cannot be cured and/or eradicated by local and/or systemic therapies. Nevertheless, cancer immune therapy should augment specific tumor immunity by using two distinct measures: enhancing the effector cell functions such as antigen presentation capacity of APCs and tumor cell killing capacity of cytotoxic cells, and reactivating the immune system in immune-suppressive tumor microenvironments. Here, we will summarize the current status and discuss the future perspective on immune therapy for HCC.
Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells(APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor immunity is frequently repressed at tumor sites. Malignantly transformed cells rarely survive the attack by the immune system, but cells that do survive change their phenotypes to reduce their immunogenicity. The resultant cells evade the attack by the immune system and form clinically discernible tumors. Tumor microenvironments simultaneously contain a wide variety of immune suppressive molecules and cells to dampen tumor immunity. Moreover, the liver microenvironment exhibits immune tolerance to reduce aberrant immune responses to massively-exposed antigens via the portal vein, and immune dysfunction is frequently associated with liver cirrhosis, which is widespread in hepatocellular carcinoma(HCC) patients. Immune therapy aims to reduce tumor burden, but it is also expected to prevent non-cancerous liver lesions from progressing to HCC, because HCC develops or recurs from noncancerous liver lesions with chronic inflammatory states and/or cirrhosis and these lesions cannot be cured and/or eradicated by local and/or systemic therapies. Nevertheless, cancer immune therapy should augment specific tumor immunity by using two distinct measures: enhancing the effector cell functions such as antigen presentation capacity of APCs and tumor cell killing capacity of cytotoxic cells, and reactivating the immune system in immune-suppressive tumor microenvironments. Here, we will summarize the current status and discuss the future perspective on immune therapy for HCC.
引文
1 Forner A,Reig M,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-1314[PMID:29307467 DOI:10.1016/S0140-6736(18)30010-2]
2 Koh WP,Robien K,Wang R,Govindarajan S,Yuan JM,Yu MC.Smoking as an independent risk factor for hepatocellular carcinoma:the Singapore Chinese Health Study.Br J Cancer 2011;105:1430-1435[PMID:21915129 DOI:10.1038/bjc.2011.360]
3 Wang C,Wang X,Gong G,Ben Q,Qiu W,Chen Y,Li G,Wang L.Increased risk of hepatocellular carcinoma in patients with diabetes mellitus:a systematic review and meta-analysis of cohort studies.Int J Cancer 2012;130:1639-1648[PMID:21544812 DOI:10.1002/ijc.26165]
4 Marengo A,Rosso C,Bugianesi E.Liver Cancer:Connections with Obesity,Fatty Liver,and Cirrhosis.Annu Rev Med 2016;67:103-117[PMID:26473416 DOI:10.1146/annurev-med-090514-013832]
5 Marquardt JU,Andersen JB,Thorgeirsson SS.Functional and genetic deconstruction of the cellular origin in liver cancer.Nat Rev Cancer 2015;15:653-667[PMID:26493646 DOI:10.1038/nrc4017]
6 Schulze K,Nault JC,Villanueva A.Genetic profiling of hepatocellular carcinoma using next-generation sequencing.JHepatol 2016;65:1031-1042[PMID:27262756 DOI:10.1016/j.jhep.2016.05.035]
7 Totoki Y,Tatsuno K,Covington KR,Ueda H,Creighton CJ,Kato M,Tsuji S,Donehower LA,Slagle BL,Nakamura H,Yamamoto S,Shinbrot E,Hama N,Lehmkuhl M,Hosoda F,Arai Y,Walker K,Dahdouli M,Gotoh K,Nagae G,Gingras MC,Muzny DM,Ojima H,Shimada K,Midorikawa Y,Goss JA,Cotton R,Hayashi A,Shibahara J,Ishikawa S,Guiteau J,Tanaka M,Urushidate T,Ohashi S,Okada N,Doddapaneni H,Wang M,Zhu Y,Dinh H,Okusaka T,Kokudo N,Kosuge T,Takayama T,Fukayama M,Gibbs RA,Wheeler DA,Aburatani H,Shibata T.Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.Nat Genet 2014;46:1267-1273[PMID:25362482 DOI:10.1038/ng.3126]
8 Satyanarayana A,Manns MP,Rudolph KL.Telomeres and telomerase:a dual role in hepatocarcinogenesis.Hepatology 2004;40:276-283[PMID:15368430 DOI:10.1002/hep.20308]
9 Schulze K,Imbeaud S,LetouzéE,Alexandrov LB,Calderaro J,Rebouissou S,Couchy G,Meiller C,Shinde J,Soysouvanh F,Calatayud AL,Pinyol R,Pelletier L,Balabaud C,Laurent A,Blanc JF,Mazzaferro V,Calvo F,Villanueva A,Nault JC,Bioulac-Sage P,Stratton MR,Llovet JM,Zucman-Rossi J.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.Nat Genet 2015;47:505-511[PMID:25822088 DOI:10.1038/ng.3252]
10 Sawey ET,Chanrion M,Cai C,Wu G,Zhang J,Zender L,Zhao A,Busuttil RW,Yee H,Stein L,French DM,Finn RS,Lowe SW,Powers S.Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.Cancer Cell 2011;19:347-358[PMID:21397858 DOI:10.1016/j.ccr.2011.01.040]
11 Horwitz E,SteinⅠ,Andreozzi M,Nemeth J,Shoham A,Pappo O,Schweitzer N,Tornillo L,Kanarek N,Quagliata L,Zreik F,Porat RM,Finkelstein R,Reuter H,Koschny R,Ganten T,Mogler C,Shibolet O,Hess J,Breuhahn K,Grunewald M,Schirmacher P,Vogel A,Terracciano L,Angel P,Ben-Neriah Y,Pikarsky E.Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.Cancer Discov 2014;4:730-743[PMID:24687604 DOI:10.1158/2159-8290.CD-13-0782]
12 Neuveut C,Wei Y,Buendia MA.Mechanisms of HBV-related hepatocarcinogenesis.J Hepatol 2010;52:594-604[PMID:20185200 DOI:10.1016/j.jhep.2009.10.033]
13 Tang H,Oishi N,Kaneko S,Murakami S.Molecular functions and biological roles of hepatitis B virus x protein.Cancer Sci 2006;97:977-983[PMID:16984372 DOI:10.1111/j.1349-7006.2006.00299.x]
14 European Association For The Study Of The Liver,European Organisation For Research And Treatment Of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma.J Hepatol 2012;56:908-943[PMID:22424438 DOI:10.1016/j.jhep.2011.12.001]
15 Bruix J,Reig M,Sherman M.Evidence-Based Diagnosis,Staging,and Treatment of Patients With Hepatocellular Carcinoma.Gastroenterology 2016;150:835-853[PMID:26795574 DOI:10.1053/j.gastro.2015.12.041]
16 Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation.Cell 2011;144:646-674[PMID:21376230 DOI:10.1016/j.cell.2011.02.013]
17 Mittal D,Gubin MM,Schreiber RD,Smyth MJ.New insights into cancer immunoediting and its three component phaseselimination,equilibrium and escape.Curr Opin Immunol 2014;27:16-25[PMID:24531241 DOI:10.1016/j.coi.2014.01.004]
18 Thomson AW,Knolle PA.Antigen-presenting cell function in the tolerogenic liver environment.Nat Rev Immunol 2010;10:753-766[PMID:20972472 DOI:10.1038/nri2858]
19 Noor MT,Manoria P.Immune Dysfunction in Cirrhosis.J Clin Transl Hepatol 2017;5:50-58[PMID:28507927 DOI:10.14218/JCTH.2016.00056]
20 Ringelhan M,Pfister D,O’Connor T,Pikarsky E,Heikenwalder M.The immunology of hepatocellular carcinoma.Nat Immunol 2018;19:222-232[PMID:29379119 DOI:10.1038/s41590-018-0044-z]
21 Obeid JM,Kunk PR,Zaydfudim VM,Bullock TN,Slingluff CL Jr.,Rahma OE.Immunotherapy for hepatocellular carcinoma patients:is it ready for prime time?Cancer Immunol Immunother 2018;67:161-174[PMID:29052780 DOI:10.1007/s00262-017-2082-z]
22 Zhang Q,Vignali DA.Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.Immunity 2016;44:1034-1051[PMID:27192568 DOI:10.1016/j.immuni.2016.04.017]
23 Chávez-Galán L,Arenas-Del Angel MC,Zenteno E,Chávez R,Lascurain R.Cell death mechanisms induced by cytotoxic lymphocytes.Cell Mol Immunol 2009;6:15-25[PMID:19254476DOI:10.1038/cmi.2009.3]
24 Dyck L,Mills KHG.Immune checkpoints and their inhibition in cancer and infectious diseases.Eur J Immunol 2017;47:765-779[PMID:28393361 DOI:10.1002/eji.201646875]
25 Elsegood CL,Tirnitz-Parker JE,Olynyk JK,Yeoh GC.Immune checkpoint inhibition:prospects for prevention and therapy of hepatocellular carcinoma.Clin Transl Immunology 2017;6:e161[PMID:29326816 DOI:10.1038/cti.2017.47]
26 Butterfield LH,Ribas A,Meng WS,Dissette VB,Amarnani S,Vu HT,Seja E,Todd K,Glaspy JA,Mc Bride WH,Economou JS.T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.Clin Cancer Res 2003;9:5902-5908[PMID:14676113]
27 Wang XP,Wang QX,Lin HP,Xu B,Zhao Q,Chen K.Recombinant heat shock protein 70 functional peptide and alphafetoprotein epitope peptide vaccine elicits specific anti-tumor immunity.Oncotarget 2016;7:71274-71284[PMID:27713135DOI:10.18632/oncotarget.12464]
28 Wang XP,Wang QX,Lin HP,Wang YL,Yang Y.Glycoprotein 96 andα-fetoprotein cross-linking complexes elicited specific antitumor immunity.Cancer Biother Radiopharm 2013;28:406-414[PMID:23484810 DOI:10.1089/cbr.2012.1404]
29 Butterfield LH,Ribas A,Potter DM,Economou JS.Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.Cancer Immunol Immunother 2007;56:1931-1943[PMID:17522860 DOI:10.1007/s00262-007-0337-9]
30 Greten TF,Forner A,Korangy F,N’Kontchou G,Barget N,Ayuso C,Ormandy LA,Manns MP,Beaugrand M,Bruix J.A phaseⅡopen label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.BMC Cancer 2010;10:209[PMID:20478057 DOI:10.1186/1471-2407-10-209]
31 Mizukoshi E,Nakagawa H,Kitahara M,Yamashita T,Arai K,Sunagozaka H,Fushimi K,Kobayashi E,Kishi H,Muraguchi A,Kaneko S.Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.Cancer Lett 2015;364:98-105[PMID:25982205 DOI:10.1016/j.canlet.2015.04.031]
32 Haruyama Y,Kataoka H.Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.World JGastroenterol 2016;22:275-283[PMID:26755876 DOI:10.3748/wjg.v22.i1.275]
33 Tsuchiya N,Yoshikawa T,Fujinami N,Saito K,Mizuno S,Sawada Y,EndoⅠ,Nakatsura T.Immunological efficacy of glypican-3peptide vaccine in patients with advanced hepatocellular carcinoma.Oncoimmunology 2017;6:e1346764[PMID:29123959 DOI:10.1080/2162402X.2017.1346764]
34 Sayem MA,Tomita Y,Yuno A,Hirayama M,Irie A,Tsukamoto H,Senju S,Yuba E,Yoshikawa T,Kono K,Nakatsura T,Nishimura Y.Identification of glypican-3-derived long peptides activating both CD8+and CD4+T cells;prolonged overall survival in cancer patients with Th cell response.Oncoimmunology 2015;5:e1062209[PMID:26942076 DOI:10.1080/2162402x.2015.1062209]
35 Tomimaru Y,Mishra S,Safran H,Charpentier KP,Martin W,De Groot AS,Gregory SH,Wands JR.Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.Vaccine 2015;33:1256-1266[PMID:25629522 DOI:10.1016/j.vaccine.2015.01.037]
36 Li Y,Cheng P,Wen Y,Chen P,Yang L,Zhao X,Lv H,Quan Q,Wu Y,Yang H,Liu J,Wen X,Liu N,Kang Z,Luo S,Wang L,Wei Y.T lymphocyte responses against hepatitis B virus-related hepatocellular carcinoma induced by adenovirus vaccine encoding HBx.Int J Mol Med 2010;26:869-876[PMID:21042781]
37 Pan QZ,Pan K,Wang QJ,Weng DS,Zhao JJ,Zheng HX,Zhang XF,Jiang SS,Lv L,Tang Y,Li YQ,He J,Liu Q,Chen CL,Zhang HX,Xia JC.Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.Stem Cells 2015;33:354-366[PMID:25267273 DOI:10.1002/stem.1850]
38 Chen Y,Huang A,Gao M,Yan Y,Zhang W.Potential therapeutic value of dendritic cells loaded with NY-ESO-1protein for the immunotherapy of advanced hepatocellular carcinoma.Int J Mol Med 2013;32:1366-1372[PMID:24085111 DOI:10.3892/ijmm.2013.1510]
39 Kumai T,Fan A,Harabuchi Y,Celis E.Cancer immunotherapy:moving forward with peptide T cell vaccines.Curr Opin Immunol 2017;47:57-63[PMID:28734176 DOI:10.1016/j.coi.2017.07.003]
40 Circelli L,Petrizzo A,Tagliamonte M,Heidenreich R,Tornesello ML,Buonaguro FM,Buonaguro L.Immunological effects of a novel RNA-based adjuvant in liver cancer patients.Cancer Immunol Immunother 2017;66:103-112[PMID:27832318DOI:10.1007/s00262-016-1923-5]
41 Lu Z,Zuo B,Jing R,Gao X,Rao Q,Liu Z,Qi H,Guo H,Yin H.Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.J Hepatol 2017;67:739-748[PMID:28549917 DOI:10.1016/j.jhep.2017.05.019]
42 Wan X,Cheng C,Lin Z,Jiang R,Zhao W,Yan X,Tang J,Yao K,Sun B,Chen Y.The attenuated hepatocellular carcinomaspecific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells.Oncotarget 2015;6:8822-8838[PMID:25826093 DOI:10.18632/oncotarget.3558]
43 Shang N,Figini M,Shangguan J,Wang B,Sun C,Pan L,Ma Q,Zhang Z.Dendritic cells based immunotherapy.Am J Cancer Res2017;7:2091-2102[PMID:29119057]
44 Osada T,Clay T,Hobeika A,Lyerly HK,Morse MA.NK cell activation by dendritic cell vaccine:a mechanism of action for clinical activity.Cancer Immunol Immunother 2006;55:1122-1131[PMID:16273350 DOI:10.1007/s00262-005-0089-3]
45 Palmer DH,Midgley RS,Mirza N,Torr EE,Ahmed F,Steele JC,Steven NM,Kerr DJ,Young LS,Adams DH.A phaseⅡstudy of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.Hepatology 2009;49:124-132[PMID:18980227 DOI:10.1002/hep.22626]
46 Butterfield LH,Ribas A,Dissette VB,Lee Y,Yang JQ,De la Rocha P,Duran SD,Hernandez J,Seja E,Potter DM,Mc Bride WH,Finn R,Glaspy JA,Economou JS.A phaseⅠ/Ⅱtrial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.Clin Cancer Res 2006;12:2817-2825[PMID:16675576 DOI:10.1158/1078-0432.ccr-05-2856]
47 Bray SM,Vujanovic L,Butterfield LH.Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.Clin Dev Immunol 2011;2011:249281[PMID:21969837 DOI:10.1155/2011/249281]
48 Liu Y,Butterfield LH,Fu X,Song Z,Zhang X,Lu C,Ding G,Wu M.Lentivirally engineered dendritic cells activate AFP-specific Tcells which inhibit hepatocellular carcinoma growth in vitro and in vivo.Int J Oncol 2011;39:245-253[PMID:21491085 DOI:10.3892/ijo.2011.1004]
49 Zhou J,Ma P,Li J,Song W.Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells pulsed with recombinant adeno-associated virus carryingα-fetoprotein gene or cancer cell lysate.Mol Med Rep 2015;11:3174-3180[PMID:25484119 DOI:10.3892/mmr.2014.3059]
50 El Ansary M,Mogawer S,Elhamid SA,Alwakil S,Aboelkasem F,Sabaawy HE,Abdelhalim O.Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.J Cancer Res Clin Oncol 2013;139:39-48[PMID:22886490 DOI:10.1007/s00432-012-1298-8]
51 Xie BH,Yang JY,Li HP,Zhang B,Chen W,Zhou B,Peng BG,Liang LJ,He Q.Dendritic cells transfected with hepatocellular carcinoma(HCC)total RNA induce specific immune responses against HCC in vitro and in vivo.Clin Transl Oncol 2014;16:753-760[PMID:24338510 DOI:10.1007/s12094-013-1145-7]
52 Wang X,Bayer ME,Chen X,Fredrickson C,Cornforth AN,Liang G,Cannon J,He J,Fu Q,Liu J,Nistor GI,Cao W,Chen C,Dillman RO.PhaseⅠtrial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma.J Surg Oncol 2015;111:862-867[PMID:25873455DOI:10.1002/jso.23897]
53 Tada F,Abe M,Hirooka M,Ikeda Y,Hiasa Y,Lee Y,Jung NC,Lee WB,Lee HS,Bae YS,Onji M.PhaseⅠ/Ⅱstudy of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.Int J Oncol 2012;41:1601-1609[PMID:22971679 DOI:10.3892/ijo.2012.1626]
54 Lee JH,Lee Y,Lee M,Heo MK,Song JS,Kim KH,Lee H,Yi NJ,Lee KW,Suh KS,Bae YS,Kim YJ.A phaseⅠ/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.Br J Cancer 2015;113:1666-1676[PMID:26657650 DOI:10.1038/bjc.2015.430]
55 Lee JH,Tak WY,Lee Y,Heo MK,Song JS,Kim HY,Park SY,Bae SH,Lee JH,Heo J,Kim KH,Bae YS,Kim YJ.Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma,randomized phaseⅡstudy.Oncoimmunology 2017;6:e1328335[PMID:28811965 DOI:10.1080/2162402X.2017.1328335]
56 Maeda Y,Yoshimura K,Matsui H,Shindo Y,Tamesa T,Tokumitsu Y,Hashimoto N,Tokuhisa Y,Sakamoto K,Sakai K,Suehiro Y,Hinoda Y,Tamada K,Yoshino S,Hazama S,Oka M.Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma:a phase 1 dose escalation clinical trial.Cancer Immunol Immunother 2015;64:1047-1056[PMID:25982372 DOI:10.1007/s00262-015-1709-1]
57 Mizukoshi E,Nakamoto Y,Arai K,Yamashita T,Mukaida N,Matsushima K,Matsui O,Kaneko S.Enhancement of tumorspecific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma.Int J Cancer2010;126:2164-2174[PMID:19739081 DOI:10.1002/ijc.24882]
58 Nakamoto Y,Mizukoshi E,Kitahara M,Arihara F,Sakai Y,Kakinoki K,Fujita Y,Marukawa Y,Arai K,Yamashita T,Mukaida N,Matsushima K,Matsui O,Kaneko S.Prolonged recurrencefree survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization.Clin Exp Immunol 2011;163:165-177[PMID:21087443 DOI:10.1111/j.1365-2249.2010.04246.x]
59 Aref AM,Hoa NT,Ge L,Agrawal A,Dacosta-Iyer M,Lambrecht N,Ouyang Y,Cornforth AN,Jadus MR.HCA519/TPX2:a potential T-cell tumor-associated antigen for human hepatocellular carcinoma.Onco Targets Ther 2014;7:1061-1070[PMID:24966688 DOI:10.2147/OTT.S61442]
60 Choi YJ,Park SJ,Park YS,Park HS,Yang KM,Heo K.Ep CAMpeptide-primed dendritic cell vaccination confers significant antitumor immunity in hepatocellular carcinoma cells.PLo S One2018;13:e0190638[PMID:29298343 DOI:10.1371/journal.pone.0190638]
61 Yang JY,Li X,Gao L,Teng ZH,Liu WC.Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity.Exp Ther Med 2012;4:655-660[PMID:23170121 DOI:10.3892/etm.2012.635]
62 Vogt A,Sievers E,Lukacs-Kornek V,Decker G,Raskopf E,Meumann N,Büning H,Sauerbruch T,Strassburg CP,SchmidtWolf IG,Gonzalez-Carmona MA.Improving immunotherapy of hepatocellular carcinoma(HCC)using dendritic cells(DC)engineered to express IL-12 in vivo.Liver Int 2014;34:447-461[PMID:23998316 DOI:10.1111/liv.12284]
63 Badalamenti G,Fanale D,Incorvaia L,Barraco N,ListìA,Maragliano R,Vincenzi B,CalòV,Iovanna JL,Bazan V,Russo A.Role of tumor-infiltrating lymphocytes in patients with solid tumors:Can a drop dig a stone?Cell Immunol 2018;pii:S0008-8749(18)30014-5[PMID:29395859 DOI:10.1016/j.cellimm.2018.01.013]
64 Hinrichs CS,Rosenberg SA.Exploiting the curative potential of adoptive T-cell therapy for cancer.Immunol Rev 2014;257:56-71[PMID:24329789 DOI:10.1111/imr.12132]
65 Rosenberg SA,Yang JC,Sherry RM,Kammula US,Hughes MS,Phan GQ,Citrin DE,Restifo NP,Robbins PF,Wunderlich JR,Morton KE,Laurencot CM,Steinberg SM,White DE,Dudley ME.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clin Cancer Res 2011;17:4550-4557[PMID:21498393 DOI:10.1158/1078-0432.CCR-11-0116]
66 Debets R,Donnadieu E,Chouaib S,Coukos G.TCR-engineered Tcells to treat tumors:Seeing but not touching?Semin Immunol 2016;28:10-21[PMID:26997556 DOI:10.1016/j.smim.2016.03.002]
67 Morgan RA,Dudley ME,Wunderlich JR,Hughes MS,Yang JC,Sherry RM,Royal RE,Topalian SL,Kammula US,Restifo NP,Zheng Z,Nahvi A,de Vries CR,Rogers-Freezer LJ,Mavroukakis SA,Rosenberg SA.Cancer regression in patients after transfer of genetically engineered lymphocytes.Science 2006;314:126-129[PMID:16946036 DOI:10.1126/science.1129003]
68 Johnson LA,Morgan RA,Dudley ME,Cassard L,Yang JC,Hughes MS,Kammula US,Royal RE,Sherry RM,Wunderlich JR,Lee CC,Restifo NP,Schwarz SL,Cogdill AP,Bishop RJ,Kim H,Brewer CC,Rudy SF,Van Waes C,Davis JL,Mathur A,Ripley RT,Nathan DA,Laurencot CM,Rosenberg SA.Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood 2009;114:535-546[PMID:19451549 DOI:10.1182/blood-2009-03-211714]
69 Hoseini SS,Cheung NV.Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.Cancer Lett 2017;399:44-52[PMID:28428075 DOI:10.1016/j.canlet.2017.04.013]
70 Gao H,Li K,Tu H,Pan X,Jiang H,Shi B,Kong J,Wang H,Yang S,Gu J,Li Z.Development of T cells redirected to glypican-3for the treatment of hepatocellular carcinoma.Clin Cancer Res2014;20:6418-6428[PMID:25320357 DOI:10.1158/1078-0432.CCR-14-1170]
71 Li W,Guo L,Rathi P,Marinova E,Gao X,Wu MF,Liu H,Dotti G,Gottschalk S,Metelitsa LS,Heczey A.Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.Hum Gene Ther 2017;28:437-448[PMID:27530312 DOI:10.1089/hum.2016.025]
72 Chen C,Li K,Jiang H,Song F,Gao H,Pan X,Shi B,Bi Y,Wang H,Wang H,Li Z.Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.Cancer Immunol Immunother 2017;66:475-489[PMID:28035433 DOI:10.1007/s00262-016-1949-8]
73 Deng Z,Wu Y,Ma W,Zhang S,Zhang YQ.Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen Ep CAM.BMC Immunol 2015;16:1[PMID:25636521 DOI:10.1186/s12865-014-0064-x]
74 Qin L,Lai Y,Zhao R,Wei X,Weng J,Lai P,Li B,Lin S,Wang S,Wu Q,Liang Q,Li Y,Zhang X,Wu Y,Liu P,Yao Y,Pei D,Du X,Li P.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.J Hematol Oncol 2017;10:68[PMID:28288656 DOI:10.1186/s13045-017-0437-8]
75 Vivier E,Tomasello E,Baratin M,Walzer T,Ugolini S.Functions of natural killer cells.Nat Immunol 2008;9:503-510[PMID:18425107 DOI:10.1038/ni1582]
76 Lanier LL.NK cell recognition.Annu Rev Immunol 2005;23:225-274[PMID:15771571 DOI:10.1146/annurev.immunol.23.021704.115526]
77 Wang W,Erbe AK,Hank JA,Morris ZS,Sondel PM.NK CellMediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.Front Immunol 2015;6:368[PMID:26284063DOI:10.3389/fimmu.2015.00368]
78 Cerwenka A,Lanier LL.Natural killer cell memory in infection,inflammation and cancer.Nat Rev Immunol 2016;16:112-123[PMID:26806484 DOI:10.1038/nri.2015.9]
79 Ruggeri L,Capanni M,Urbani E,Perruccio K,Shlomchik WD,Tosti A,Posati S,Rogaia D,Frassoni F,Aversa F,Martelli MF,Velardi A.Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science 2002;295:2097-2100[PMID:11896281 DOI:10.1126/science.1068440]
80 Male V.Liver-Resident NK Cells:The Human Factor.Trends Immunol 2017;38:307-309[PMID:28318877 DOI:10.1016/j.it.2017.02.008]
81 von Karstedt S,Montinaro A,Walczak H.Exploring the TRAILs less travelled:TRAIL in cancer biology and therapy.Nat Rev Cancer2017;17:352-366[PMID:28536452 DOI:10.1038/nrc.2017.28]
82 Nishida S,Levi DM,Tzakis AG.Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.Curr Opin Organ Transplant 2013;18:690-694[PMID:24220052 DOI:10.1097/MOT.0000000000000024]
83 Nair S,Dhodapkar MV.Natural Killer T Cells in Cancer Immunotherapy.Front Immunol 2017;8:1178[PMID:29018445 DOI:10.3389/fimmu.2017.01178]
84 Margalit M,Shibolet O,Klein A,Elinav E,Alper R,Thalenfeld B,Engelhardt D,Rabbani E,Ilan Y.Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKTlymphocytes.Int J Cancer 2005;115:443-449[PMID:15688366DOI:10.1002/ijc.20889]
85 Jiang J,Wu C,Lu B.Cytokine-induced killer cells promote antitumor immunity.J Transl Med 2013;11:83[PMID:23536996DOI:10.1186/1479-5876-11-83]
86 Franceschetti M,Pievani A,Borleri G,Vago L,Fleischhauer K,Golay J,Introna M.Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.Exp Hematol 2009;37:616-628.e2[PMID:19375652 DOI:10.1016/j.exphem.2009.01.010]
87 Morisaki T,Onishi H,Koya N,Kiyota A,Tanaka H,Umebayashi M,Ogino T,NagamatsuⅠ,Katano M.Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system.Anticancer Res 2011;31:2505-2510[PMID:21873167]
88 Introna M,Correnti F.Innovative Clinical Perspectives for CIK Cells in Cancer Patients.Int J Mol Sci 2018;19:pii:E358[PMID:29370095 DOI:10.3390/ijms19020358]
89 Hontscha C,Borck Y,Zhou H,Messmer D,Schmidt-Wolf IG.Clinical trials on CIK cells:first report of the international registry on CIK cells(IRCC).J Cancer Res Clin Oncol 2011;137:305-310[PMID:20407789 DOI:10.1007/s00432-010-0887-7]
90 Yu R,Yang B,Chi X,Cai L,Liu C,Yang L,Wang X,He P,Lu X.Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma:a systematic review and meta-analysis.Drug Des Devel Ther 2017;11:851-864[PMID:28360510 DOI:10.2147/DDDT.S124399]
91 Zhou P,Liang P,Dong B,Yu X,Han Z,Xu Y.PhaseⅠclinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma.Cancer Biol Ther 2011;11:450-456[PMID:21258206 DOI:10.4161/cbt.11.5.14669]
92 Coulie PG,Van den Eynde BJ,van der Bruggen P,Boon T.Tumour antigens recognized by T lymphocytes:at the core of cancer immunotherapy.Nat Rev Cancer 2014;14:135-146[PMID:24457417 DOI:10.1038/nrc3670]
93 Rosenberg SA,Sherry RM,Morton KE,Scharfman WJ,Yang JC,Topalian SL,Royal RE,Kammula U,Restifo NP,Hughes MS,Schwartzentruber D,Berman DM,Schwarz SL,Ngo LT,Mavroukakis SA,White DE,Steinberg SM.Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+T cells in patients with melanoma.JImmunol 2005;175:6169-6176[PMID:16237114 DOI:10.4049/jimmunol.175.9.6169]
94 Zarour HM.Reversing T-cell Dysfunction and Exhaustion in Cancer.Clin Cancer Res 2016;22:1856-1864[PMID:27084739DOI:10.1158/1078-0432.CCR-15-1849]
95 Sharma P,Allison JP.The future of immune checkpoint therapy.Science 2015;348:56-61[PMID:25838373 DOI:10.1126/science.aaa8172]
96 Rowshanravan B,Halliday N,Sansom DM.CTLA-4:a moving target in immunotherapy.Blood 2018;131:58-67[PMID:29118008 DOI:10.1182/blood-2017-06-741033]
97 Sakaguchi S,Wing K,Onishi Y,Prieto-Martin P,Yamaguchi T.Regulatory T cells:how do they suppress immune responses?Int Immunol 2009;21:1105-1111[PMID:19737784 DOI:10.1093/intimm/dxp095]
98 Sangro B,Gomez-Martin C,de la Mata M,I?arrairaegui M,Garralda E,Barrera P,Riezu-Boj JI,Larrea E,Alfaro C,Sarobe P,Lasarte JJ,Pérez-Gracia JL,MeleroⅠ,Prieto J.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.J Hepatol 2013;59:81-88[PMID:23466307 DOI:10.1016/j.jhep.2013.02.022]
99 Duffy AG,Ulahannan SV,Makorova-Rusher O,Rahma O,Wedemeyer H,Pratt D,Davis JL,Hughes MS,Heller T,El Gindi M,Uppala A,Korangy F,Kleiner DE,Figg WD,Venzon D,Steinberg SM,Venkatesan AM,Krishnasamy V,Abi-Jaoudeh N,Levy E,Wood BJ,Greten TF.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol 2017;66:545-551[PMID:27816492 DOI:10.1016/j.jhep.2016.10.029]
100 Bardhan K,Anagnostou T,Boussiotis VA.The PD1:PD-L1/2Pathway from Discovery to Clinical Implementation.Front Immunol 2016;7:550[PMID:28018338 DOI:10.3389/fimmu.2016.00550]
101 Wang BJ,Bao JJ,Wang JZ,Wang Y,Jiang M,Xing MY,Zhang WG,Qi JY,Roggendorf M,Lu MJ,Yang DL.Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.World J Gastroenterol 2011;17:3322-3329[PMID:21876620 DOI:10.3748/wjg.v17.i28.3322]
102 Gao Q,Wang XY,Qiu SJ,YamatoⅠ,Sho M,Nakajima Y,Zhou J,Li BZ,Shi YH,Xiao YS,Xu Y,Fan J.Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.Clin Cancer Res 2009;15:971-979[PMID:19188168 DOI:10.1158/1078-0432.CCR-08-1608]
103 Topalian SL,Hodi FS,Brahmer JR,Gettinger SN,Smith DC,Mc Dermott DF,Powderly JD,Carvajal RD,Sosman JA,Atkins MB,Leming PD,Spigel DR,Antonia SJ,Horn L,Drake CG,Pardoll DM,Chen L,Sharfman WH,Anders RA,Taube JM,Mc Miller TL,Xu H,Korman AJ,Jure-Kunkel M,Agrawal S,Mc Donald D,Kollia GD,Gupta A,Wigginton JM,Sznol M.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med 2012;366:2443-2454[PMID:22658127DOI:10.1056/NEJMoa1200690]
104 Brahmer JR,Tykodi SS,Chow LQ,Hwu WJ,Topalian SL,Hwu P,Drake CG,Camacho LH,Kauh J,Odunsi K,Pitot HC,Hamid O,Bhatia S,Martins R,Eaton K,Chen S,Salay TM,Alaparthy S,Grosso JF,Korman AJ,Parker SM,Agrawal S,Goldberg SM,Pardoll DM,Gupta A,Wigginton JM.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med 2012;366:2455-2465[PMID:22658128 DOI:10.1056/NEJMoa1200694]
105 El-Khoueiry AB,Sangro B,Yau T,Crocenzi TS,Kudo M,Hsu C,Kim TY,Choo SP,Trojan J,Welling TH Rd,Meyer T,Kang YK,Yeo W,Chopra A,Anderson J,Dela Cruz C,Lang L,Neely J,Tang H,Dastani HB,MeleroⅠ.Nivolumab in patients with advanced hepatocellular carcinoma(Check Mate 040):an open-label,noncomparative,phase 1/2 dose escalation and expansion trial.Lancet 2017;389:2492-2502[PMID:28434648 DOI:10.1016/S0140-6736(17)31046-2]
106 Weiskopf K.Cancer immunotherapy targeting the CD47/SIRPαaxis.Eur J Cancer 2017;76:100-109[PMID:28286286 DOI:10.1016/j.ejca.2017.02.013]
107 Chao MP,Alizadeh AA,Tang C,Myklebust JH,Varghese B,Gill S,Jan M,Cha AC,Chan CK,Tan BT,Park CY,Zhao F,Kohrt HE,Malumbres R,Briones J,Gascoyne RD,Lossos IS,Levy R,Weissman IL,Majeti R.Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.Cell 2010;142:699-713[PMID:20813259 DOI:10.1016/j.cell.2010.07.044]
108 Edris B,Weiskopf K,Volkmer AK,Volkmer JP,Willingham SB,Contreras-Trujillo H,Liu J,Majeti R,West RB,Fletcher JA,Beck AH,Weissman IL,van de Rijn M.Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.Proc Natl Acad Sci USA 2012;109:6656-6661[PMID:22451919 DOI:10.1073/pnas.1121629109]
109 Weiskopf K,Jahchan NS,Schnorr PJ,Cristea S,Ring AM,Maute RL,Volkmer AK,Volkmer JP,Liu J,Lim JS,Yang D,Seitz G,Nguyen T,Wu D,Jude K,Guerston H,Barkal A,Trapani F,George J,Poirier JT,Gardner EE,Miles LA,de Stanchina E,Lofgren SM,Vogel H,Winslow MM,Dive C,Thomas RK,Rudin CM,van de Rijn M,Majeti R,Garcia KC,Weissman IL,Sage J.CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.J Clin Invest 2016;126:2610-2620[PMID:27294525 DOI:10.1172/JCI81603]
110 Zhang M,Hutter G,Kahn SA,Azad TD,Gholamin S,Xu CY,Liu J,Achrol AS,Richard C,Sommerkamp P,Schoen MK,Mc Cracken MN,Majeti R,WeissmanⅠ,Mitra SS,Cheshier SH.Anti-CD47Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.PLo S One 2016;11:e0153550[PMID:27092773 DOI:10.1371/journal.pone.0153550]
111 Triebel F.LAG-3:a regulator of T-cell and DC responses and its use in therapeutic vaccination.Trends Immunol 2003;24:619-622[PMID:14644131 DOI:10.1016/j.it.2003.10.001]
112 He Y,Rivard CJ,Rozeboom L,Yu H,Ellison K,Kowalewski A,Zhou C,Hirsch FR.Lymphocyte-activation gene-3,an important immune checkpoint in cancer.Cancer Sci 2016;107:1193-1197[PMID:27297395 DOI:10.1111/cas.12986]
113 Das M,Zhu C,Kuchroo VK.Tim-3 and its role in regulating anti-tumor immunity.Immunol Rev 2017;276:97-111[PMID:28258697 DOI:10.1111/imr.12520]
114 Fourcade J,Sun Z,Benallaoua M,Guillaume P,Luescher IF,Sander C,Kirkwood JM,Kuchroo V,Zarour HM.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients.J Exp Med 2010;207:2175-2186[PMID:20819923 DOI:10.1084/jem.20100637]
115 Sakuishi K,Apetoh L,Sullivan JM,Blazar BR,Kuchroo VK,Anderson AC.Targeting Tim-3 and PD-1 pathways to reverse Tcell exhaustion and restore anti-tumor immunity.J Exp Med 2010;207:2187-2194[PMID:20819927 DOI:10.1084/jem.20100643]
116 Murphy TL,Murphy KM.Slow down and survive:Enigmatic immunoregulation by BTLA and HVEM.Annu Rev Immunol2010;28:389-411[PMID:20307212 DOI:10.1146/annurevimmunol-030409-101202]
117 Pasero C,Olive D.Interfering with coinhibitory molecules:BTLA/HVEM as new targets to enhance anti-tumor immunity.Immunol Lett 2013;151:71-75[PMID:23439006 DOI:10.1016/j.imlet.2013.01.008]
118 DerréL,Rivals JP,Jandus C,Pastor S,Rimoldi D,Romero P,Michielin O,Olive D,Speiser DE.BTLA mediates inhibition of human tumor-specific CD8+T cells that can be partially reversed by vaccination.J Clin Invest 2010;120:157-167[PMID:20038811 DOI:10.1172/JCI40070]
119 Dougall WC,Kurtulus S,Smyth MJ,Anderson AC.TIGIT and CD96:new checkpoint receptor targets for cancer immunotherapy.Immunol Rev 2017;276:112-120[PMID:28258695 DOI:10.1111/imr.12518]
120 Meng X,Huang Z,Teng F,Xing L,Yu J.Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.Cancer Treat Rev 2015;41:868-876[PMID:26589760 DOI:10.1016/j.ctrv.2015.11.001]
121 Topalian SL,Taube JM,Anders RA,Pardoll DM.Mechanismdriven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer 2016;16:275-287[PMID:27079802DOI:10.1038/nrc.2016.36]
122 Chowell D,Morris LGT,Grigg CM,Weber JK,Samstein RM,Makarov V,Kuo F,Kendall SM,Requena D,Riaz N,Greenbaum B,Carroll J,Garon E,Hyman DM,Zehir A,Solit D,Berger M,Zhou R,Rizvi NA,Chan TA.Patient HLA classⅠgenotype influences cancer response to checkpoint blockade immunotherapy.Science 2018;359:582-587[PMID:29217585 DOI:10.1126/science.aao4572]
123 Wilson RAM,Evans TRJ,Fraser AR,Nibbs RJB.Immune checkpoint inhibitors:new strategies to checkmate cancer.Clin Exp Immunol2018;191:133-148[PMID:29139554 DOI:10.1111/cei.13081]
124 Brix N,Tiefenthaller A,Anders H,Belka C,Lauber K.Abscopal,immunological effects of radiotherapy:Narrowing the gap between clinical and preclinical experiences.Immunol Rev 2017;280:249-279[PMID:29027221 DOI:10.1111/imr.12573]
125 Saxena M,Bhardwaj N.Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.Trends Cancer 2018;4:119-137[PMID:29458962 DOI:10.1016/j.trecan.2017.12.007]
126 Tanaka A,Sakaguchi S.Regulatory T cells in cancer immunotherapy.Cell Res 2017;27:109-118[PMID:27995907 DOI:10.1038/cr.2016.151]
127 Shang B,Liu Y,Jiang SJ,Liu Y.Prognostic value of tumorinfiltrating Fox P3+regulatory T cells in cancers:a systematic review and meta-analysis.Sci Rep 2015;5:15179[PMID:26462617 DOI:10.1038/srep15179]
128 Mathai AM,Kapadia MJ,Alexander J,Kernochan LE,Swanson PE,Yeh MM.Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.Am J Surg Pathol 2012;36:980-986[PMID:22446942 DOI:10.1097/PAS.0b013e31824e9b7c]
129 Arce Vargas F,Furness AJS,SolomonⅠ,Joshi K,Mekkaoui L,Lesko MH,Miranda Rota E,Dahan R,Georgiou A,Sledzinska A,Ben Aissa A,Franz D,Werner Sunderland M,Wong YNS,Henry JY,O’Brien T,Nicol D,Challacombe B,Beers SA;Melanoma TRACERx Consortium;Renal TRACERx Consortium;Lung TRACERx Consortium,Turajlic S,Gore M,Larkin J,Swanton C,Chester KA,Pule M,Ravetch JV,Marafioti T,Peggs KS,Quezada SA.Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Immunity 2017;46:577-586[PMID:28410988 DOI:10.1016/j.immuni.2017.03.013]
130 Sugiyama D,Nishikawa H,Maeda Y,Nishioka M,Tanemura A,KatayamaⅠ,Ezoe S,Kanakura Y,Sato E,Fukumori Y,Karbach J,J?ger E,Sakaguchi S.Anti-CCR4 m Ab selectively depletes effector-type Fox P3+CD4+regulatory T cells,evoking antitumor immune responses in humans.Proc Natl Acad Sci USA 2013;110:17945-17950[PMID:24127572 DOI:10.1073/pnas.1316796110]
131 Nocentini G,Riccardi C.GITR:a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily.Eur JImmunol 2005;35:1016-1022[PMID:15770698 DOI:10.1002/eji.200425818]
132 Hu P,Arias RS,Sadun RE,Nien YC,Zhang N,Sabzevari H,Lutsiak ME,Khawli LA,Epstein AL.Construction and preclinical characterization of Fc-m GITRL for the immunotherapy of cancer.Clin Cancer Res 2008;14:579-588[PMID:18223234 DOI:10.1158/1078-0432.CCR-07-0940]
133 Ko K,Yamazaki S,Nakamura K,Nishioka T,Hirota K,Yamaguchi T,Shimizu J,Nomura T,Chiba T,Sakaguchi S.Treatment of advanced tumors with agonistic anti-GITR m Ab and its effects on tumorinfiltrating Foxp3+CD25+CD4+regulatory T cells.J Exp Med 2005;202:885-891[PMID:16186187 DOI:10.1084/jem.20050940]
134 Knee DA,Hewes B,Brogdon JL.Rationale for anti-GITR cancer immunotherapy.Eur J Cancer 2016;67:1-10[PMID:27591414DOI:10.1016/j.ejca.2016.06.028]
135 Veglia F,Perego M,Gabrilovich D.Myeloid-derived suppressor cells coming of age.Nat Immunol 2018;19:108-119[PMID:29348500 DOI:10.1038/s41590-017-0022-x]
136 Sun HL,Zhou X,Xue YF,Wang K,Shen YF,Mao JJ,Guo HF,Miao ZN.Increased frequency and clinical significance of myeloidderived suppressor cells in human colorectal carcinoma.World J Gastroenterol 2012;18:3303-3309[PMID:22783056 DOI:10.3748/wjg.v18.i25.3303]
137 Zhang B,Wang Z,Wu L,Zhang M,Li W,Ding J,Zhu J,Wei H,Zhao K.Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.PLo S One 2013;8:e57114[PMID:23437326 DOI:10.1371/journal.pone.0057114]
138 Arihara F,Mizukoshi E,Kitahara M,Takata Y,Arai K,Yamashita T,Nakamoto Y,Kaneko S.Increase in CD14+HLA-DR-/low myeloidderived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.Cancer Immunol Immunother 2013;62:1421-1430[PMID:23764929 DOI:10.1007/s00262-013-1447-1]
139 Suzuki E,Kapoor V,Jassar AS,Kaiser LR,Albelda SM.Gemcitabine selectively eliminates splenic Gr-1+/CD11b+myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.Clin Cancer Res 2005;11:6713-6721[PMID:16166452 DOI:10.1158/1078-0432.ccr-05-0883]
140 Vincent J,Mignot G,Chalmin F,Ladoire S,Bruchard M,Chevriaux A,Martin F,Apetoh L,RébéC,Ghiringhelli F.5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.Cancer Res 2010;70:3052-3061[PMID:20388795DOI:10.1158/0008-5472.CAN-09-3690]
141 Zhang Z,Yu X,Wang Z,Wu P,Huang J.Anthracyclines potentiate anti-tumor immunity:A new opportunity for chemoimmunotherapy.Cancer Lett 2015;369:331-335[PMID:26454214 DOI:10.1016/j.canlet.2015.10.002]
142 Davis RJ,Moore EC,Clavijo PE,Friedman J,Cash H,Chen Z,Silvin C,Van Waes C,Allen C.Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.Cancer Res 2017;77:2607-2619[PMID:28364000 DOI:10.1158/0008-5472.CAN-16-2534]
143 Liu JF,Deng WW,Chen L,Li YC,Wu L,Ma SR,Zhang WF,Bu LL,Sun ZJ.Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.Mol Carcinog 2018;57:429-439[PMID:29215754DOI:10.1002/mc.22767]
144 Highfill SL,Cui Y,Giles AJ,Smith JP,Zhang H,Morse E,Kaplan RN,Mackall CL.Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.Sci Transl Med 2014;6:237ra67[PMID:24848257 DOI:10.1126/scitranslmed.3007974]
2 Koh WP,Robien K,Wang R,Govindarajan S,Yuan JM,Yu MC.Smoking as an independent risk factor for hepatocellular carcinoma:the Singapore Chinese Health Study.Br J Cancer 2011;105:1430-1435[PMID:21915129 DOI:10.1038/bjc.2011.360]
3 Wang C,Wang X,Gong G,Ben Q,Qiu W,Chen Y,Li G,Wang L.Increased risk of hepatocellular carcinoma in patients with diabetes mellitus:a systematic review and meta-analysis of cohort studies.Int J Cancer 2012;130:1639-1648[PMID:21544812 DOI:10.1002/ijc.26165]
4 Marengo A,Rosso C,Bugianesi E.Liver Cancer:Connections with Obesity,Fatty Liver,and Cirrhosis.Annu Rev Med 2016;67:103-117[PMID:26473416 DOI:10.1146/annurev-med-090514-013832]
5 Marquardt JU,Andersen JB,Thorgeirsson SS.Functional and genetic deconstruction of the cellular origin in liver cancer.Nat Rev Cancer 2015;15:653-667[PMID:26493646 DOI:10.1038/nrc4017]
6 Schulze K,Nault JC,Villanueva A.Genetic profiling of hepatocellular carcinoma using next-generation sequencing.JHepatol 2016;65:1031-1042[PMID:27262756 DOI:10.1016/j.jhep.2016.05.035]
7 Totoki Y,Tatsuno K,Covington KR,Ueda H,Creighton CJ,Kato M,Tsuji S,Donehower LA,Slagle BL,Nakamura H,Yamamoto S,Shinbrot E,Hama N,Lehmkuhl M,Hosoda F,Arai Y,Walker K,Dahdouli M,Gotoh K,Nagae G,Gingras MC,Muzny DM,Ojima H,Shimada K,Midorikawa Y,Goss JA,Cotton R,Hayashi A,Shibahara J,Ishikawa S,Guiteau J,Tanaka M,Urushidate T,Ohashi S,Okada N,Doddapaneni H,Wang M,Zhu Y,Dinh H,Okusaka T,Kokudo N,Kosuge T,Takayama T,Fukayama M,Gibbs RA,Wheeler DA,Aburatani H,Shibata T.Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.Nat Genet 2014;46:1267-1273[PMID:25362482 DOI:10.1038/ng.3126]
8 Satyanarayana A,Manns MP,Rudolph KL.Telomeres and telomerase:a dual role in hepatocarcinogenesis.Hepatology 2004;40:276-283[PMID:15368430 DOI:10.1002/hep.20308]
9 Schulze K,Imbeaud S,LetouzéE,Alexandrov LB,Calderaro J,Rebouissou S,Couchy G,Meiller C,Shinde J,Soysouvanh F,Calatayud AL,Pinyol R,Pelletier L,Balabaud C,Laurent A,Blanc JF,Mazzaferro V,Calvo F,Villanueva A,Nault JC,Bioulac-Sage P,Stratton MR,Llovet JM,Zucman-Rossi J.Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.Nat Genet 2015;47:505-511[PMID:25822088 DOI:10.1038/ng.3252]
10 Sawey ET,Chanrion M,Cai C,Wu G,Zhang J,Zender L,Zhao A,Busuttil RW,Yee H,Stein L,French DM,Finn RS,Lowe SW,Powers S.Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.Cancer Cell 2011;19:347-358[PMID:21397858 DOI:10.1016/j.ccr.2011.01.040]
11 Horwitz E,SteinⅠ,Andreozzi M,Nemeth J,Shoham A,Pappo O,Schweitzer N,Tornillo L,Kanarek N,Quagliata L,Zreik F,Porat RM,Finkelstein R,Reuter H,Koschny R,Ganten T,Mogler C,Shibolet O,Hess J,Breuhahn K,Grunewald M,Schirmacher P,Vogel A,Terracciano L,Angel P,Ben-Neriah Y,Pikarsky E.Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.Cancer Discov 2014;4:730-743[PMID:24687604 DOI:10.1158/2159-8290.CD-13-0782]
12 Neuveut C,Wei Y,Buendia MA.Mechanisms of HBV-related hepatocarcinogenesis.J Hepatol 2010;52:594-604[PMID:20185200 DOI:10.1016/j.jhep.2009.10.033]
13 Tang H,Oishi N,Kaneko S,Murakami S.Molecular functions and biological roles of hepatitis B virus x protein.Cancer Sci 2006;97:977-983[PMID:16984372 DOI:10.1111/j.1349-7006.2006.00299.x]
14 European Association For The Study Of The Liver,European Organisation For Research And Treatment Of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma.J Hepatol 2012;56:908-943[PMID:22424438 DOI:10.1016/j.jhep.2011.12.001]
15 Bruix J,Reig M,Sherman M.Evidence-Based Diagnosis,Staging,and Treatment of Patients With Hepatocellular Carcinoma.Gastroenterology 2016;150:835-853[PMID:26795574 DOI:10.1053/j.gastro.2015.12.041]
16 Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation.Cell 2011;144:646-674[PMID:21376230 DOI:10.1016/j.cell.2011.02.013]
17 Mittal D,Gubin MM,Schreiber RD,Smyth MJ.New insights into cancer immunoediting and its three component phaseselimination,equilibrium and escape.Curr Opin Immunol 2014;27:16-25[PMID:24531241 DOI:10.1016/j.coi.2014.01.004]
18 Thomson AW,Knolle PA.Antigen-presenting cell function in the tolerogenic liver environment.Nat Rev Immunol 2010;10:753-766[PMID:20972472 DOI:10.1038/nri2858]
19 Noor MT,Manoria P.Immune Dysfunction in Cirrhosis.J Clin Transl Hepatol 2017;5:50-58[PMID:28507927 DOI:10.14218/JCTH.2016.00056]
20 Ringelhan M,Pfister D,O’Connor T,Pikarsky E,Heikenwalder M.The immunology of hepatocellular carcinoma.Nat Immunol 2018;19:222-232[PMID:29379119 DOI:10.1038/s41590-018-0044-z]
21 Obeid JM,Kunk PR,Zaydfudim VM,Bullock TN,Slingluff CL Jr.,Rahma OE.Immunotherapy for hepatocellular carcinoma patients:is it ready for prime time?Cancer Immunol Immunother 2018;67:161-174[PMID:29052780 DOI:10.1007/s00262-017-2082-z]
22 Zhang Q,Vignali DA.Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.Immunity 2016;44:1034-1051[PMID:27192568 DOI:10.1016/j.immuni.2016.04.017]
23 Chávez-Galán L,Arenas-Del Angel MC,Zenteno E,Chávez R,Lascurain R.Cell death mechanisms induced by cytotoxic lymphocytes.Cell Mol Immunol 2009;6:15-25[PMID:19254476DOI:10.1038/cmi.2009.3]
24 Dyck L,Mills KHG.Immune checkpoints and their inhibition in cancer and infectious diseases.Eur J Immunol 2017;47:765-779[PMID:28393361 DOI:10.1002/eji.201646875]
25 Elsegood CL,Tirnitz-Parker JE,Olynyk JK,Yeoh GC.Immune checkpoint inhibition:prospects for prevention and therapy of hepatocellular carcinoma.Clin Transl Immunology 2017;6:e161[PMID:29326816 DOI:10.1038/cti.2017.47]
26 Butterfield LH,Ribas A,Meng WS,Dissette VB,Amarnani S,Vu HT,Seja E,Todd K,Glaspy JA,Mc Bride WH,Economou JS.T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.Clin Cancer Res 2003;9:5902-5908[PMID:14676113]
27 Wang XP,Wang QX,Lin HP,Xu B,Zhao Q,Chen K.Recombinant heat shock protein 70 functional peptide and alphafetoprotein epitope peptide vaccine elicits specific anti-tumor immunity.Oncotarget 2016;7:71274-71284[PMID:27713135DOI:10.18632/oncotarget.12464]
28 Wang XP,Wang QX,Lin HP,Wang YL,Yang Y.Glycoprotein 96 andα-fetoprotein cross-linking complexes elicited specific antitumor immunity.Cancer Biother Radiopharm 2013;28:406-414[PMID:23484810 DOI:10.1089/cbr.2012.1404]
29 Butterfield LH,Ribas A,Potter DM,Economou JS.Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.Cancer Immunol Immunother 2007;56:1931-1943[PMID:17522860 DOI:10.1007/s00262-007-0337-9]
30 Greten TF,Forner A,Korangy F,N’Kontchou G,Barget N,Ayuso C,Ormandy LA,Manns MP,Beaugrand M,Bruix J.A phaseⅡopen label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.BMC Cancer 2010;10:209[PMID:20478057 DOI:10.1186/1471-2407-10-209]
31 Mizukoshi E,Nakagawa H,Kitahara M,Yamashita T,Arai K,Sunagozaka H,Fushimi K,Kobayashi E,Kishi H,Muraguchi A,Kaneko S.Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.Cancer Lett 2015;364:98-105[PMID:25982205 DOI:10.1016/j.canlet.2015.04.031]
32 Haruyama Y,Kataoka H.Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.World JGastroenterol 2016;22:275-283[PMID:26755876 DOI:10.3748/wjg.v22.i1.275]
33 Tsuchiya N,Yoshikawa T,Fujinami N,Saito K,Mizuno S,Sawada Y,EndoⅠ,Nakatsura T.Immunological efficacy of glypican-3peptide vaccine in patients with advanced hepatocellular carcinoma.Oncoimmunology 2017;6:e1346764[PMID:29123959 DOI:10.1080/2162402X.2017.1346764]
34 Sayem MA,Tomita Y,Yuno A,Hirayama M,Irie A,Tsukamoto H,Senju S,Yuba E,Yoshikawa T,Kono K,Nakatsura T,Nishimura Y.Identification of glypican-3-derived long peptides activating both CD8+and CD4+T cells;prolonged overall survival in cancer patients with Th cell response.Oncoimmunology 2015;5:e1062209[PMID:26942076 DOI:10.1080/2162402x.2015.1062209]
35 Tomimaru Y,Mishra S,Safran H,Charpentier KP,Martin W,De Groot AS,Gregory SH,Wands JR.Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.Vaccine 2015;33:1256-1266[PMID:25629522 DOI:10.1016/j.vaccine.2015.01.037]
36 Li Y,Cheng P,Wen Y,Chen P,Yang L,Zhao X,Lv H,Quan Q,Wu Y,Yang H,Liu J,Wen X,Liu N,Kang Z,Luo S,Wang L,Wei Y.T lymphocyte responses against hepatitis B virus-related hepatocellular carcinoma induced by adenovirus vaccine encoding HBx.Int J Mol Med 2010;26:869-876[PMID:21042781]
37 Pan QZ,Pan K,Wang QJ,Weng DS,Zhao JJ,Zheng HX,Zhang XF,Jiang SS,Lv L,Tang Y,Li YQ,He J,Liu Q,Chen CL,Zhang HX,Xia JC.Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.Stem Cells 2015;33:354-366[PMID:25267273 DOI:10.1002/stem.1850]
38 Chen Y,Huang A,Gao M,Yan Y,Zhang W.Potential therapeutic value of dendritic cells loaded with NY-ESO-1protein for the immunotherapy of advanced hepatocellular carcinoma.Int J Mol Med 2013;32:1366-1372[PMID:24085111 DOI:10.3892/ijmm.2013.1510]
39 Kumai T,Fan A,Harabuchi Y,Celis E.Cancer immunotherapy:moving forward with peptide T cell vaccines.Curr Opin Immunol 2017;47:57-63[PMID:28734176 DOI:10.1016/j.coi.2017.07.003]
40 Circelli L,Petrizzo A,Tagliamonte M,Heidenreich R,Tornesello ML,Buonaguro FM,Buonaguro L.Immunological effects of a novel RNA-based adjuvant in liver cancer patients.Cancer Immunol Immunother 2017;66:103-112[PMID:27832318DOI:10.1007/s00262-016-1923-5]
41 Lu Z,Zuo B,Jing R,Gao X,Rao Q,Liu Z,Qi H,Guo H,Yin H.Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.J Hepatol 2017;67:739-748[PMID:28549917 DOI:10.1016/j.jhep.2017.05.019]
42 Wan X,Cheng C,Lin Z,Jiang R,Zhao W,Yan X,Tang J,Yao K,Sun B,Chen Y.The attenuated hepatocellular carcinomaspecific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells.Oncotarget 2015;6:8822-8838[PMID:25826093 DOI:10.18632/oncotarget.3558]
43 Shang N,Figini M,Shangguan J,Wang B,Sun C,Pan L,Ma Q,Zhang Z.Dendritic cells based immunotherapy.Am J Cancer Res2017;7:2091-2102[PMID:29119057]
44 Osada T,Clay T,Hobeika A,Lyerly HK,Morse MA.NK cell activation by dendritic cell vaccine:a mechanism of action for clinical activity.Cancer Immunol Immunother 2006;55:1122-1131[PMID:16273350 DOI:10.1007/s00262-005-0089-3]
45 Palmer DH,Midgley RS,Mirza N,Torr EE,Ahmed F,Steele JC,Steven NM,Kerr DJ,Young LS,Adams DH.A phaseⅡstudy of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.Hepatology 2009;49:124-132[PMID:18980227 DOI:10.1002/hep.22626]
46 Butterfield LH,Ribas A,Dissette VB,Lee Y,Yang JQ,De la Rocha P,Duran SD,Hernandez J,Seja E,Potter DM,Mc Bride WH,Finn R,Glaspy JA,Economou JS.A phaseⅠ/Ⅱtrial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.Clin Cancer Res 2006;12:2817-2825[PMID:16675576 DOI:10.1158/1078-0432.ccr-05-2856]
47 Bray SM,Vujanovic L,Butterfield LH.Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients.Clin Dev Immunol 2011;2011:249281[PMID:21969837 DOI:10.1155/2011/249281]
48 Liu Y,Butterfield LH,Fu X,Song Z,Zhang X,Lu C,Ding G,Wu M.Lentivirally engineered dendritic cells activate AFP-specific Tcells which inhibit hepatocellular carcinoma growth in vitro and in vivo.Int J Oncol 2011;39:245-253[PMID:21491085 DOI:10.3892/ijo.2011.1004]
49 Zhou J,Ma P,Li J,Song W.Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells pulsed with recombinant adeno-associated virus carryingα-fetoprotein gene or cancer cell lysate.Mol Med Rep 2015;11:3174-3180[PMID:25484119 DOI:10.3892/mmr.2014.3059]
50 El Ansary M,Mogawer S,Elhamid SA,Alwakil S,Aboelkasem F,Sabaawy HE,Abdelhalim O.Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.J Cancer Res Clin Oncol 2013;139:39-48[PMID:22886490 DOI:10.1007/s00432-012-1298-8]
51 Xie BH,Yang JY,Li HP,Zhang B,Chen W,Zhou B,Peng BG,Liang LJ,He Q.Dendritic cells transfected with hepatocellular carcinoma(HCC)total RNA induce specific immune responses against HCC in vitro and in vivo.Clin Transl Oncol 2014;16:753-760[PMID:24338510 DOI:10.1007/s12094-013-1145-7]
52 Wang X,Bayer ME,Chen X,Fredrickson C,Cornforth AN,Liang G,Cannon J,He J,Fu Q,Liu J,Nistor GI,Cao W,Chen C,Dillman RO.PhaseⅠtrial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma.J Surg Oncol 2015;111:862-867[PMID:25873455DOI:10.1002/jso.23897]
53 Tada F,Abe M,Hirooka M,Ikeda Y,Hiasa Y,Lee Y,Jung NC,Lee WB,Lee HS,Bae YS,Onji M.PhaseⅠ/Ⅱstudy of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.Int J Oncol 2012;41:1601-1609[PMID:22971679 DOI:10.3892/ijo.2012.1626]
54 Lee JH,Lee Y,Lee M,Heo MK,Song JS,Kim KH,Lee H,Yi NJ,Lee KW,Suh KS,Bae YS,Kim YJ.A phaseⅠ/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.Br J Cancer 2015;113:1666-1676[PMID:26657650 DOI:10.1038/bjc.2015.430]
55 Lee JH,Tak WY,Lee Y,Heo MK,Song JS,Kim HY,Park SY,Bae SH,Lee JH,Heo J,Kim KH,Bae YS,Kim YJ.Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma,randomized phaseⅡstudy.Oncoimmunology 2017;6:e1328335[PMID:28811965 DOI:10.1080/2162402X.2017.1328335]
56 Maeda Y,Yoshimura K,Matsui H,Shindo Y,Tamesa T,Tokumitsu Y,Hashimoto N,Tokuhisa Y,Sakamoto K,Sakai K,Suehiro Y,Hinoda Y,Tamada K,Yoshino S,Hazama S,Oka M.Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma:a phase 1 dose escalation clinical trial.Cancer Immunol Immunother 2015;64:1047-1056[PMID:25982372 DOI:10.1007/s00262-015-1709-1]
57 Mizukoshi E,Nakamoto Y,Arai K,Yamashita T,Mukaida N,Matsushima K,Matsui O,Kaneko S.Enhancement of tumorspecific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma.Int J Cancer2010;126:2164-2174[PMID:19739081 DOI:10.1002/ijc.24882]
58 Nakamoto Y,Mizukoshi E,Kitahara M,Arihara F,Sakai Y,Kakinoki K,Fujita Y,Marukawa Y,Arai K,Yamashita T,Mukaida N,Matsushima K,Matsui O,Kaneko S.Prolonged recurrencefree survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization.Clin Exp Immunol 2011;163:165-177[PMID:21087443 DOI:10.1111/j.1365-2249.2010.04246.x]
59 Aref AM,Hoa NT,Ge L,Agrawal A,Dacosta-Iyer M,Lambrecht N,Ouyang Y,Cornforth AN,Jadus MR.HCA519/TPX2:a potential T-cell tumor-associated antigen for human hepatocellular carcinoma.Onco Targets Ther 2014;7:1061-1070[PMID:24966688 DOI:10.2147/OTT.S61442]
60 Choi YJ,Park SJ,Park YS,Park HS,Yang KM,Heo K.Ep CAMpeptide-primed dendritic cell vaccination confers significant antitumor immunity in hepatocellular carcinoma cells.PLo S One2018;13:e0190638[PMID:29298343 DOI:10.1371/journal.pone.0190638]
61 Yang JY,Li X,Gao L,Teng ZH,Liu WC.Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity.Exp Ther Med 2012;4:655-660[PMID:23170121 DOI:10.3892/etm.2012.635]
62 Vogt A,Sievers E,Lukacs-Kornek V,Decker G,Raskopf E,Meumann N,Büning H,Sauerbruch T,Strassburg CP,SchmidtWolf IG,Gonzalez-Carmona MA.Improving immunotherapy of hepatocellular carcinoma(HCC)using dendritic cells(DC)engineered to express IL-12 in vivo.Liver Int 2014;34:447-461[PMID:23998316 DOI:10.1111/liv.12284]
63 Badalamenti G,Fanale D,Incorvaia L,Barraco N,ListìA,Maragliano R,Vincenzi B,CalòV,Iovanna JL,Bazan V,Russo A.Role of tumor-infiltrating lymphocytes in patients with solid tumors:Can a drop dig a stone?Cell Immunol 2018;pii:S0008-8749(18)30014-5[PMID:29395859 DOI:10.1016/j.cellimm.2018.01.013]
64 Hinrichs CS,Rosenberg SA.Exploiting the curative potential of adoptive T-cell therapy for cancer.Immunol Rev 2014;257:56-71[PMID:24329789 DOI:10.1111/imr.12132]
65 Rosenberg SA,Yang JC,Sherry RM,Kammula US,Hughes MS,Phan GQ,Citrin DE,Restifo NP,Robbins PF,Wunderlich JR,Morton KE,Laurencot CM,Steinberg SM,White DE,Dudley ME.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clin Cancer Res 2011;17:4550-4557[PMID:21498393 DOI:10.1158/1078-0432.CCR-11-0116]
66 Debets R,Donnadieu E,Chouaib S,Coukos G.TCR-engineered Tcells to treat tumors:Seeing but not touching?Semin Immunol 2016;28:10-21[PMID:26997556 DOI:10.1016/j.smim.2016.03.002]
67 Morgan RA,Dudley ME,Wunderlich JR,Hughes MS,Yang JC,Sherry RM,Royal RE,Topalian SL,Kammula US,Restifo NP,Zheng Z,Nahvi A,de Vries CR,Rogers-Freezer LJ,Mavroukakis SA,Rosenberg SA.Cancer regression in patients after transfer of genetically engineered lymphocytes.Science 2006;314:126-129[PMID:16946036 DOI:10.1126/science.1129003]
68 Johnson LA,Morgan RA,Dudley ME,Cassard L,Yang JC,Hughes MS,Kammula US,Royal RE,Sherry RM,Wunderlich JR,Lee CC,Restifo NP,Schwarz SL,Cogdill AP,Bishop RJ,Kim H,Brewer CC,Rudy SF,Van Waes C,Davis JL,Mathur A,Ripley RT,Nathan DA,Laurencot CM,Rosenberg SA.Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood 2009;114:535-546[PMID:19451549 DOI:10.1182/blood-2009-03-211714]
69 Hoseini SS,Cheung NV.Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.Cancer Lett 2017;399:44-52[PMID:28428075 DOI:10.1016/j.canlet.2017.04.013]
70 Gao H,Li K,Tu H,Pan X,Jiang H,Shi B,Kong J,Wang H,Yang S,Gu J,Li Z.Development of T cells redirected to glypican-3for the treatment of hepatocellular carcinoma.Clin Cancer Res2014;20:6418-6428[PMID:25320357 DOI:10.1158/1078-0432.CCR-14-1170]
71 Li W,Guo L,Rathi P,Marinova E,Gao X,Wu MF,Liu H,Dotti G,Gottschalk S,Metelitsa LS,Heczey A.Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.Hum Gene Ther 2017;28:437-448[PMID:27530312 DOI:10.1089/hum.2016.025]
72 Chen C,Li K,Jiang H,Song F,Gao H,Pan X,Shi B,Bi Y,Wang H,Wang H,Li Z.Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.Cancer Immunol Immunother 2017;66:475-489[PMID:28035433 DOI:10.1007/s00262-016-1949-8]
73 Deng Z,Wu Y,Ma W,Zhang S,Zhang YQ.Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen Ep CAM.BMC Immunol 2015;16:1[PMID:25636521 DOI:10.1186/s12865-014-0064-x]
74 Qin L,Lai Y,Zhao R,Wei X,Weng J,Lai P,Li B,Lin S,Wang S,Wu Q,Liang Q,Li Y,Zhang X,Wu Y,Liu P,Yao Y,Pei D,Du X,Li P.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.J Hematol Oncol 2017;10:68[PMID:28288656 DOI:10.1186/s13045-017-0437-8]
75 Vivier E,Tomasello E,Baratin M,Walzer T,Ugolini S.Functions of natural killer cells.Nat Immunol 2008;9:503-510[PMID:18425107 DOI:10.1038/ni1582]
76 Lanier LL.NK cell recognition.Annu Rev Immunol 2005;23:225-274[PMID:15771571 DOI:10.1146/annurev.immunol.23.021704.115526]
77 Wang W,Erbe AK,Hank JA,Morris ZS,Sondel PM.NK CellMediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.Front Immunol 2015;6:368[PMID:26284063DOI:10.3389/fimmu.2015.00368]
78 Cerwenka A,Lanier LL.Natural killer cell memory in infection,inflammation and cancer.Nat Rev Immunol 2016;16:112-123[PMID:26806484 DOI:10.1038/nri.2015.9]
79 Ruggeri L,Capanni M,Urbani E,Perruccio K,Shlomchik WD,Tosti A,Posati S,Rogaia D,Frassoni F,Aversa F,Martelli MF,Velardi A.Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science 2002;295:2097-2100[PMID:11896281 DOI:10.1126/science.1068440]
80 Male V.Liver-Resident NK Cells:The Human Factor.Trends Immunol 2017;38:307-309[PMID:28318877 DOI:10.1016/j.it.2017.02.008]
81 von Karstedt S,Montinaro A,Walczak H.Exploring the TRAILs less travelled:TRAIL in cancer biology and therapy.Nat Rev Cancer2017;17:352-366[PMID:28536452 DOI:10.1038/nrc.2017.28]
82 Nishida S,Levi DM,Tzakis AG.Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.Curr Opin Organ Transplant 2013;18:690-694[PMID:24220052 DOI:10.1097/MOT.0000000000000024]
83 Nair S,Dhodapkar MV.Natural Killer T Cells in Cancer Immunotherapy.Front Immunol 2017;8:1178[PMID:29018445 DOI:10.3389/fimmu.2017.01178]
84 Margalit M,Shibolet O,Klein A,Elinav E,Alper R,Thalenfeld B,Engelhardt D,Rabbani E,Ilan Y.Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKTlymphocytes.Int J Cancer 2005;115:443-449[PMID:15688366DOI:10.1002/ijc.20889]
85 Jiang J,Wu C,Lu B.Cytokine-induced killer cells promote antitumor immunity.J Transl Med 2013;11:83[PMID:23536996DOI:10.1186/1479-5876-11-83]
86 Franceschetti M,Pievani A,Borleri G,Vago L,Fleischhauer K,Golay J,Introna M.Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.Exp Hematol 2009;37:616-628.e2[PMID:19375652 DOI:10.1016/j.exphem.2009.01.010]
87 Morisaki T,Onishi H,Koya N,Kiyota A,Tanaka H,Umebayashi M,Ogino T,NagamatsuⅠ,Katano M.Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system.Anticancer Res 2011;31:2505-2510[PMID:21873167]
88 Introna M,Correnti F.Innovative Clinical Perspectives for CIK Cells in Cancer Patients.Int J Mol Sci 2018;19:pii:E358[PMID:29370095 DOI:10.3390/ijms19020358]
89 Hontscha C,Borck Y,Zhou H,Messmer D,Schmidt-Wolf IG.Clinical trials on CIK cells:first report of the international registry on CIK cells(IRCC).J Cancer Res Clin Oncol 2011;137:305-310[PMID:20407789 DOI:10.1007/s00432-010-0887-7]
90 Yu R,Yang B,Chi X,Cai L,Liu C,Yang L,Wang X,He P,Lu X.Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma:a systematic review and meta-analysis.Drug Des Devel Ther 2017;11:851-864[PMID:28360510 DOI:10.2147/DDDT.S124399]
91 Zhou P,Liang P,Dong B,Yu X,Han Z,Xu Y.PhaseⅠclinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma.Cancer Biol Ther 2011;11:450-456[PMID:21258206 DOI:10.4161/cbt.11.5.14669]
92 Coulie PG,Van den Eynde BJ,van der Bruggen P,Boon T.Tumour antigens recognized by T lymphocytes:at the core of cancer immunotherapy.Nat Rev Cancer 2014;14:135-146[PMID:24457417 DOI:10.1038/nrc3670]
93 Rosenberg SA,Sherry RM,Morton KE,Scharfman WJ,Yang JC,Topalian SL,Royal RE,Kammula U,Restifo NP,Hughes MS,Schwartzentruber D,Berman DM,Schwarz SL,Ngo LT,Mavroukakis SA,White DE,Steinberg SM.Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+T cells in patients with melanoma.JImmunol 2005;175:6169-6176[PMID:16237114 DOI:10.4049/jimmunol.175.9.6169]
94 Zarour HM.Reversing T-cell Dysfunction and Exhaustion in Cancer.Clin Cancer Res 2016;22:1856-1864[PMID:27084739DOI:10.1158/1078-0432.CCR-15-1849]
95 Sharma P,Allison JP.The future of immune checkpoint therapy.Science 2015;348:56-61[PMID:25838373 DOI:10.1126/science.aaa8172]
96 Rowshanravan B,Halliday N,Sansom DM.CTLA-4:a moving target in immunotherapy.Blood 2018;131:58-67[PMID:29118008 DOI:10.1182/blood-2017-06-741033]
97 Sakaguchi S,Wing K,Onishi Y,Prieto-Martin P,Yamaguchi T.Regulatory T cells:how do they suppress immune responses?Int Immunol 2009;21:1105-1111[PMID:19737784 DOI:10.1093/intimm/dxp095]
98 Sangro B,Gomez-Martin C,de la Mata M,I?arrairaegui M,Garralda E,Barrera P,Riezu-Boj JI,Larrea E,Alfaro C,Sarobe P,Lasarte JJ,Pérez-Gracia JL,MeleroⅠ,Prieto J.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.J Hepatol 2013;59:81-88[PMID:23466307 DOI:10.1016/j.jhep.2013.02.022]
99 Duffy AG,Ulahannan SV,Makorova-Rusher O,Rahma O,Wedemeyer H,Pratt D,Davis JL,Hughes MS,Heller T,El Gindi M,Uppala A,Korangy F,Kleiner DE,Figg WD,Venzon D,Steinberg SM,Venkatesan AM,Krishnasamy V,Abi-Jaoudeh N,Levy E,Wood BJ,Greten TF.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol 2017;66:545-551[PMID:27816492 DOI:10.1016/j.jhep.2016.10.029]
100 Bardhan K,Anagnostou T,Boussiotis VA.The PD1:PD-L1/2Pathway from Discovery to Clinical Implementation.Front Immunol 2016;7:550[PMID:28018338 DOI:10.3389/fimmu.2016.00550]
101 Wang BJ,Bao JJ,Wang JZ,Wang Y,Jiang M,Xing MY,Zhang WG,Qi JY,Roggendorf M,Lu MJ,Yang DL.Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.World J Gastroenterol 2011;17:3322-3329[PMID:21876620 DOI:10.3748/wjg.v17.i28.3322]
102 Gao Q,Wang XY,Qiu SJ,YamatoⅠ,Sho M,Nakajima Y,Zhou J,Li BZ,Shi YH,Xiao YS,Xu Y,Fan J.Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.Clin Cancer Res 2009;15:971-979[PMID:19188168 DOI:10.1158/1078-0432.CCR-08-1608]
103 Topalian SL,Hodi FS,Brahmer JR,Gettinger SN,Smith DC,Mc Dermott DF,Powderly JD,Carvajal RD,Sosman JA,Atkins MB,Leming PD,Spigel DR,Antonia SJ,Horn L,Drake CG,Pardoll DM,Chen L,Sharfman WH,Anders RA,Taube JM,Mc Miller TL,Xu H,Korman AJ,Jure-Kunkel M,Agrawal S,Mc Donald D,Kollia GD,Gupta A,Wigginton JM,Sznol M.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med 2012;366:2443-2454[PMID:22658127DOI:10.1056/NEJMoa1200690]
104 Brahmer JR,Tykodi SS,Chow LQ,Hwu WJ,Topalian SL,Hwu P,Drake CG,Camacho LH,Kauh J,Odunsi K,Pitot HC,Hamid O,Bhatia S,Martins R,Eaton K,Chen S,Salay TM,Alaparthy S,Grosso JF,Korman AJ,Parker SM,Agrawal S,Goldberg SM,Pardoll DM,Gupta A,Wigginton JM.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med 2012;366:2455-2465[PMID:22658128 DOI:10.1056/NEJMoa1200694]
105 El-Khoueiry AB,Sangro B,Yau T,Crocenzi TS,Kudo M,Hsu C,Kim TY,Choo SP,Trojan J,Welling TH Rd,Meyer T,Kang YK,Yeo W,Chopra A,Anderson J,Dela Cruz C,Lang L,Neely J,Tang H,Dastani HB,MeleroⅠ.Nivolumab in patients with advanced hepatocellular carcinoma(Check Mate 040):an open-label,noncomparative,phase 1/2 dose escalation and expansion trial.Lancet 2017;389:2492-2502[PMID:28434648 DOI:10.1016/S0140-6736(17)31046-2]
106 Weiskopf K.Cancer immunotherapy targeting the CD47/SIRPαaxis.Eur J Cancer 2017;76:100-109[PMID:28286286 DOI:10.1016/j.ejca.2017.02.013]
107 Chao MP,Alizadeh AA,Tang C,Myklebust JH,Varghese B,Gill S,Jan M,Cha AC,Chan CK,Tan BT,Park CY,Zhao F,Kohrt HE,Malumbres R,Briones J,Gascoyne RD,Lossos IS,Levy R,Weissman IL,Majeti R.Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.Cell 2010;142:699-713[PMID:20813259 DOI:10.1016/j.cell.2010.07.044]
108 Edris B,Weiskopf K,Volkmer AK,Volkmer JP,Willingham SB,Contreras-Trujillo H,Liu J,Majeti R,West RB,Fletcher JA,Beck AH,Weissman IL,van de Rijn M.Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.Proc Natl Acad Sci USA 2012;109:6656-6661[PMID:22451919 DOI:10.1073/pnas.1121629109]
109 Weiskopf K,Jahchan NS,Schnorr PJ,Cristea S,Ring AM,Maute RL,Volkmer AK,Volkmer JP,Liu J,Lim JS,Yang D,Seitz G,Nguyen T,Wu D,Jude K,Guerston H,Barkal A,Trapani F,George J,Poirier JT,Gardner EE,Miles LA,de Stanchina E,Lofgren SM,Vogel H,Winslow MM,Dive C,Thomas RK,Rudin CM,van de Rijn M,Majeti R,Garcia KC,Weissman IL,Sage J.CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.J Clin Invest 2016;126:2610-2620[PMID:27294525 DOI:10.1172/JCI81603]
110 Zhang M,Hutter G,Kahn SA,Azad TD,Gholamin S,Xu CY,Liu J,Achrol AS,Richard C,Sommerkamp P,Schoen MK,Mc Cracken MN,Majeti R,WeissmanⅠ,Mitra SS,Cheshier SH.Anti-CD47Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.PLo S One 2016;11:e0153550[PMID:27092773 DOI:10.1371/journal.pone.0153550]
111 Triebel F.LAG-3:a regulator of T-cell and DC responses and its use in therapeutic vaccination.Trends Immunol 2003;24:619-622[PMID:14644131 DOI:10.1016/j.it.2003.10.001]
112 He Y,Rivard CJ,Rozeboom L,Yu H,Ellison K,Kowalewski A,Zhou C,Hirsch FR.Lymphocyte-activation gene-3,an important immune checkpoint in cancer.Cancer Sci 2016;107:1193-1197[PMID:27297395 DOI:10.1111/cas.12986]
113 Das M,Zhu C,Kuchroo VK.Tim-3 and its role in regulating anti-tumor immunity.Immunol Rev 2017;276:97-111[PMID:28258697 DOI:10.1111/imr.12520]
114 Fourcade J,Sun Z,Benallaoua M,Guillaume P,Luescher IF,Sander C,Kirkwood JM,Kuchroo V,Zarour HM.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients.J Exp Med 2010;207:2175-2186[PMID:20819923 DOI:10.1084/jem.20100637]
115 Sakuishi K,Apetoh L,Sullivan JM,Blazar BR,Kuchroo VK,Anderson AC.Targeting Tim-3 and PD-1 pathways to reverse Tcell exhaustion and restore anti-tumor immunity.J Exp Med 2010;207:2187-2194[PMID:20819927 DOI:10.1084/jem.20100643]
116 Murphy TL,Murphy KM.Slow down and survive:Enigmatic immunoregulation by BTLA and HVEM.Annu Rev Immunol2010;28:389-411[PMID:20307212 DOI:10.1146/annurevimmunol-030409-101202]
117 Pasero C,Olive D.Interfering with coinhibitory molecules:BTLA/HVEM as new targets to enhance anti-tumor immunity.Immunol Lett 2013;151:71-75[PMID:23439006 DOI:10.1016/j.imlet.2013.01.008]
118 DerréL,Rivals JP,Jandus C,Pastor S,Rimoldi D,Romero P,Michielin O,Olive D,Speiser DE.BTLA mediates inhibition of human tumor-specific CD8+T cells that can be partially reversed by vaccination.J Clin Invest 2010;120:157-167[PMID:20038811 DOI:10.1172/JCI40070]
119 Dougall WC,Kurtulus S,Smyth MJ,Anderson AC.TIGIT and CD96:new checkpoint receptor targets for cancer immunotherapy.Immunol Rev 2017;276:112-120[PMID:28258695 DOI:10.1111/imr.12518]
120 Meng X,Huang Z,Teng F,Xing L,Yu J.Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.Cancer Treat Rev 2015;41:868-876[PMID:26589760 DOI:10.1016/j.ctrv.2015.11.001]
121 Topalian SL,Taube JM,Anders RA,Pardoll DM.Mechanismdriven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer 2016;16:275-287[PMID:27079802DOI:10.1038/nrc.2016.36]
122 Chowell D,Morris LGT,Grigg CM,Weber JK,Samstein RM,Makarov V,Kuo F,Kendall SM,Requena D,Riaz N,Greenbaum B,Carroll J,Garon E,Hyman DM,Zehir A,Solit D,Berger M,Zhou R,Rizvi NA,Chan TA.Patient HLA classⅠgenotype influences cancer response to checkpoint blockade immunotherapy.Science 2018;359:582-587[PMID:29217585 DOI:10.1126/science.aao4572]
123 Wilson RAM,Evans TRJ,Fraser AR,Nibbs RJB.Immune checkpoint inhibitors:new strategies to checkmate cancer.Clin Exp Immunol2018;191:133-148[PMID:29139554 DOI:10.1111/cei.13081]
124 Brix N,Tiefenthaller A,Anders H,Belka C,Lauber K.Abscopal,immunological effects of radiotherapy:Narrowing the gap between clinical and preclinical experiences.Immunol Rev 2017;280:249-279[PMID:29027221 DOI:10.1111/imr.12573]
125 Saxena M,Bhardwaj N.Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.Trends Cancer 2018;4:119-137[PMID:29458962 DOI:10.1016/j.trecan.2017.12.007]
126 Tanaka A,Sakaguchi S.Regulatory T cells in cancer immunotherapy.Cell Res 2017;27:109-118[PMID:27995907 DOI:10.1038/cr.2016.151]
127 Shang B,Liu Y,Jiang SJ,Liu Y.Prognostic value of tumorinfiltrating Fox P3+regulatory T cells in cancers:a systematic review and meta-analysis.Sci Rep 2015;5:15179[PMID:26462617 DOI:10.1038/srep15179]
128 Mathai AM,Kapadia MJ,Alexander J,Kernochan LE,Swanson PE,Yeh MM.Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.Am J Surg Pathol 2012;36:980-986[PMID:22446942 DOI:10.1097/PAS.0b013e31824e9b7c]
129 Arce Vargas F,Furness AJS,SolomonⅠ,Joshi K,Mekkaoui L,Lesko MH,Miranda Rota E,Dahan R,Georgiou A,Sledzinska A,Ben Aissa A,Franz D,Werner Sunderland M,Wong YNS,Henry JY,O’Brien T,Nicol D,Challacombe B,Beers SA;Melanoma TRACERx Consortium;Renal TRACERx Consortium;Lung TRACERx Consortium,Turajlic S,Gore M,Larkin J,Swanton C,Chester KA,Pule M,Ravetch JV,Marafioti T,Peggs KS,Quezada SA.Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Immunity 2017;46:577-586[PMID:28410988 DOI:10.1016/j.immuni.2017.03.013]
130 Sugiyama D,Nishikawa H,Maeda Y,Nishioka M,Tanemura A,KatayamaⅠ,Ezoe S,Kanakura Y,Sato E,Fukumori Y,Karbach J,J?ger E,Sakaguchi S.Anti-CCR4 m Ab selectively depletes effector-type Fox P3+CD4+regulatory T cells,evoking antitumor immune responses in humans.Proc Natl Acad Sci USA 2013;110:17945-17950[PMID:24127572 DOI:10.1073/pnas.1316796110]
131 Nocentini G,Riccardi C.GITR:a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily.Eur JImmunol 2005;35:1016-1022[PMID:15770698 DOI:10.1002/eji.200425818]
132 Hu P,Arias RS,Sadun RE,Nien YC,Zhang N,Sabzevari H,Lutsiak ME,Khawli LA,Epstein AL.Construction and preclinical characterization of Fc-m GITRL for the immunotherapy of cancer.Clin Cancer Res 2008;14:579-588[PMID:18223234 DOI:10.1158/1078-0432.CCR-07-0940]
133 Ko K,Yamazaki S,Nakamura K,Nishioka T,Hirota K,Yamaguchi T,Shimizu J,Nomura T,Chiba T,Sakaguchi S.Treatment of advanced tumors with agonistic anti-GITR m Ab and its effects on tumorinfiltrating Foxp3+CD25+CD4+regulatory T cells.J Exp Med 2005;202:885-891[PMID:16186187 DOI:10.1084/jem.20050940]
134 Knee DA,Hewes B,Brogdon JL.Rationale for anti-GITR cancer immunotherapy.Eur J Cancer 2016;67:1-10[PMID:27591414DOI:10.1016/j.ejca.2016.06.028]
135 Veglia F,Perego M,Gabrilovich D.Myeloid-derived suppressor cells coming of age.Nat Immunol 2018;19:108-119[PMID:29348500 DOI:10.1038/s41590-017-0022-x]
136 Sun HL,Zhou X,Xue YF,Wang K,Shen YF,Mao JJ,Guo HF,Miao ZN.Increased frequency and clinical significance of myeloidderived suppressor cells in human colorectal carcinoma.World J Gastroenterol 2012;18:3303-3309[PMID:22783056 DOI:10.3748/wjg.v18.i25.3303]
137 Zhang B,Wang Z,Wu L,Zhang M,Li W,Ding J,Zhu J,Wei H,Zhao K.Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.PLo S One 2013;8:e57114[PMID:23437326 DOI:10.1371/journal.pone.0057114]
138 Arihara F,Mizukoshi E,Kitahara M,Takata Y,Arai K,Yamashita T,Nakamoto Y,Kaneko S.Increase in CD14+HLA-DR-/low myeloidderived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.Cancer Immunol Immunother 2013;62:1421-1430[PMID:23764929 DOI:10.1007/s00262-013-1447-1]
139 Suzuki E,Kapoor V,Jassar AS,Kaiser LR,Albelda SM.Gemcitabine selectively eliminates splenic Gr-1+/CD11b+myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.Clin Cancer Res 2005;11:6713-6721[PMID:16166452 DOI:10.1158/1078-0432.ccr-05-0883]
140 Vincent J,Mignot G,Chalmin F,Ladoire S,Bruchard M,Chevriaux A,Martin F,Apetoh L,RébéC,Ghiringhelli F.5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.Cancer Res 2010;70:3052-3061[PMID:20388795DOI:10.1158/0008-5472.CAN-09-3690]
141 Zhang Z,Yu X,Wang Z,Wu P,Huang J.Anthracyclines potentiate anti-tumor immunity:A new opportunity for chemoimmunotherapy.Cancer Lett 2015;369:331-335[PMID:26454214 DOI:10.1016/j.canlet.2015.10.002]
142 Davis RJ,Moore EC,Clavijo PE,Friedman J,Cash H,Chen Z,Silvin C,Van Waes C,Allen C.Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.Cancer Res 2017;77:2607-2619[PMID:28364000 DOI:10.1158/0008-5472.CAN-16-2534]
143 Liu JF,Deng WW,Chen L,Li YC,Wu L,Ma SR,Zhang WF,Bu LL,Sun ZJ.Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.Mol Carcinog 2018;57:429-439[PMID:29215754DOI:10.1002/mc.22767]
144 Highfill SL,Cui Y,Giles AJ,Smith JP,Zhang H,Morse E,Kaplan RN,Mackall CL.Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.Sci Transl Med 2014;6:237ra67[PMID:24848257 DOI:10.1126/scitranslmed.3007974]